TEAM
PhD Eng. EWELINA PAWLUS-CZERNIEJEWSKA
Chief Executive Officer
PhD Eng. Ewelina Pawlus-Czerniejewska is a graduate of Wrocław University of Science and Technology, where she earned an MSc in Biotechnology with a specialisation in Pharmaceutical Biotechnology (2011), followed by a PhD in Chemistry, specialising in Analytical Chemistry (2016).
She also completed postgraduate studies in Advanced Project Management at the Wrocław University of Economics (2020).
She has completed numerous specialist training courses in pharmaceutical law and quality systems (GLP, GMP, ISO 17025), analytical techniques (liquid and gas chromatography), food safety and control (HACCP), and analytical method validation.
She co-authored two patent applications and several scientific publications in journals indexed on the Philadelphia List. She has served as both a contributor and coordinator in scientific and research-and-development projects. She combines the development of her scientific career with professional work in a startup environment. Ewelina Pawlus-Czerniejewska also serves as Chair of the Supervisory Board of Bioceltix S.A., a company listed on the Warsaw Stock Exchange.
PhD Eng. PAWEŁ WIELGUS
Member of the Management Board
PhD Eng. Paweł Wielgus holds an MSc in Biotechnology (Wrocław University of Science and Technology, 2004), a degree in Financial Analysis (Wrocław University of Economics, 2009), and a PhD in Chemistry (Wrocław University of Science and Technology, 2010). He was a scholarship holder of the International Max Planck Research School doctoral programme (2005–2008) and a recipient of a research grant awarded by the State Committee for Scientific Research (2009–2010).
He has served as a scientific consultant and research intern at Jackson State University, Mississippi, USA (2004, 2005), and at the Max Planck Institute for Solid State Research in Dresden (2005–2007).
He is a Member of the Management Board of Kvarko Group ASI sp. z o.o. and Chief Executive Officer of Kvarko ASI S.A., investment funds focused on innovative scientific and technology-based companies built on unique, proprietary solutions with the potential to deliver a clear market advantage.
Previously, he was professionally associated with Wrocław Research Centre EIT+ sp. z o.o. Between 2008 and 2010, he worked for the Polish Individual Investors Association, an organisation representing stock market investors in Central and Eastern Europe, and subsequently served as Chair of the Audit Committee of the Association until 2017.
Earlier in his career, he was an academic lecturer and the author of numerous scientific publications in the field of quantum and computational chemistry. He has also served as a member of supervisory boards of listed companies. His professional experience is supported by the analysis of several hundred projects and hands-on investment activity, including successful equity entry and exit
PhD Eng. ROBERT KOŁODZIEJCZYK
R&D Project Manager
PhD Eng. Robert Kołodziejczyk holds an MSc in Biotechnology with a focus on molecular biology and biocatalysis (Wrocław University of Science and Technology, 2000) and a PhD in Chemistry, specialising in protein biochemistry (Wrocław University of Science and Technology, 2005). From 2006 to 2009, he served as an Assistant Professor at Adam Mickiewicz University in Poznań (Faculty of Chemistry, Department of Crystallography), while simultaneously conducting research collaboration with the Biocrystallography Research Centre at the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznań.
He was a research scientist at the University of Helsinki, Finland (Biochemistry Division, Biocentre 2, and Institute of Biotechnology, Biocentre 3) from 2010 to 2013, and subsequently at the University of Leeds, United Kingdom (School of Biomedical Sciences, Faculty of Biological Sciences) from 2013 to 2015. He also held the position of Visiting Scientist at the University of Helsinki between 2014 and 2016.
Robert Kołodziejczyk has held senior R&D and leadership roles at Pure Biologics S.A. (2015–2024) and Captor Therapeutics S.A. (2017–2019). He has extensive experience in immuno-oncology projects, covering the full drug development lifecycle from concept to execution, including the advancement of two drug candidates to Phase 0 clinical trials approved by the U.S. Food and Drug Administration (FDA).
He has completed numerous specialist training programmes in project and team management, communication, leadership, and CMC regulatory requirements for biological medicinal products. He is a recipient of the Pol-Postdoc II award (2006) and multiple national and international scientific awards. From 2007 to 2010, he was a member of the Committee on Crystallography of the Polish Academy of Sciences.
He also co-developed a commercialisation project funded by the Finnish innovation agency TEKES (2014–2015), is a graduate of the Mini MBA programme at Aston American University, USA (2017), and a former academic lecturer (2000–2006). He is the author of scientific publications in the field of protein biochemistry and has served as project leader, contributor, and consultant in numerous scientific research projects
M.Sc. Eng. MARCIN CEBULA
Chief Technologist
Marcin Cebula is a graduate of the Wrocław University of Environmental and Life Sciences, where he earned an MSc in Agricultural and Forestry Engineering, with a specialisation in Agri-Food Engineering (2009). He has completed numerous professional courses and system-based training programmes in GMP/GHP, HACCP, food safety management in accordance with the ISO 22000 standard, and food safety system auditing.
He was professionally associated for many years with Wrocław Technology Park S.A. (2010–2020), where he was involved in R&D projects and the scale-up of technological processes at the Park’s pilot facility, covering chemical and supercritical extraction, hydrolysis, encapsulation, as well as product formulation and packaging.